Standard care
OtherPatient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
NCT Number: NCT04671485
HYMACO is a monocentric, randomized comparative pilot study with a total duration of 25 months. The purpose of this study is to evaluate the effectiveness of autoHYpnosis by anchoring in the prevention of anxiety related to wearing the mask for radiotherapy of head and neck tumors.
60 patients will be randomized into 3 arms ARM A : Standard care ARM B : Autohypnosis ARM C : Musicotherapy This study is carried out during the first 5 radiotherapy sessions because this is decisive for the good progress of subsequent sessions
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.
The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions
the patient will choose the music he want to listen from a music database (3 specific moods).
The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions
Time frame: 5 weeks
Anxiety will be assessed by the maximum value obtained on the STAI form Y-A questionnaire (state anxiety) on the following 3 measurements: on the centering scanner, at the first and 5th radiotherapy session.
Time frame: 5 weeks
Anxiety will also be assessed by a digital rating scale (0 to 10), in the centering or radiotherapy scanner room, just before making the mask before the centering scan and before fitting the mask before each of the first five radiotherapy sessions
Time frame: 5 weeks
The good conduct of the centering scanner and radiotherapy session is determined by:
Time frame: 1 hour
The duration of the conditioning hypnosis session will be collected by the hypnopractor manipulator
Time frame: 5 weeks
Corresponds to the time difference in minutes between the actual time of making and wearing the compression mask for the centering scanner and wearing a compression mask for the first 5 radiotherapy sessions and the time estimated by the patient
Time frame: 1 hour
The patient's feelings will be evaluate a questionnaire composed of 5 questions already used in a previous study
Time frame: 1 hour
Assesing by the hypnopractor manipulator at the end of the session using a digital rating scale (0 to 10).
Institut de Cancérologie de Lorraine
Other
Randomized, Comparative Pilot Study Evaluating the Effectiveness of autoHYpnosis by Anchoring in the Prevention of Anxiety Related to Wearing the Mask for Radiotherapy of Head and Neck Tumors
Acronym: HYMACO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02855723
Head and Neck Neoplasms, Head and Neck Tumors
Montpellier, France
View Trial DetailsNCT06479811
Carcinoma, Cranial Nerve Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07595666
ALS - Amyotrophic Lateral Sclerosis, Alzheimer s Disease
Leuven, Vlaams-Brabant, Belgium
View Trial DetailsNCT07552467
Astrocytoma, Breast Cancer
Wuhan, Hubei, China
View Trial Details